85
Participants
Start Date
December 18, 2013
Primary Completion Date
January 10, 2020
Study Completion Date
January 10, 2020
CVA21/pembrolizumab
St Vincent's Hospital, Melbourne, Fitzroy
Epworth HealthCare, Richmond
Monash Health, Clayton
Barwon Health, Geelong
Tasman Oncology Research, Southport
St John of God Healthcare, Subiaco
Memorial Sloan Kettering Cancer Center, New York
Fox Chase Cancer Center, Philadelphia
University of Miami, Coral Gables
Karmanos Cancer Institute, Detroit
Advocate Health, Niles
UT Southwestern, Dallas
Huntsman Cancer Institute, Salt Lake City
John Wayne Cancer Institute, Santa Monica
Providence Portland Medical Center, Portland
Royal Marsden NHS Foundation Trust, Chelsea
Royal Surrey County Hospital, Guildford
St. James University Hospital, Leeds
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Viralytics
INDUSTRY